- Home
- EDF vs VRXA Comparison
EDF vs VRXA Comparison
Compare EDF & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | VRXA |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 157.0M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EDF | VRXA |
|---|---|---|
| Price | $4.38 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 161.4K | ★ 248.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $0.99 |
| 52 Week High | $5.67 | $4.50 |
Technical Indicators
Market Signals| Indicator | EDF | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 30.26 | 38.41 |
| Support Level | N/A | $1.04 |
| Resistance Level | $5.41 | $1.41 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 3.35 | 17.81 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.